reported that the ARF–Mdm2–p53 tumor suppressor axis is regulated by STAT3, and loss of STAT3 signal transduction increases the risk of prostate cancer metastasis and recurrence in mouse models, indicating a poor outcome after treatment with IL‐6/STAT3 inhibitors.48, 54. This evidence concerns the gene STAT3 and prostate carcinoma.